Alfresa Holdings (2784) FY2027 Q1 Earnings Report

Quick View

Executive Summary

This financial result was characterized by higher revenue but lower earnings, with the inability to convert revenue growth into profit being its most significant feature. Revenue increased to ¥788.96B (+4.1% YoY), while Operating Income declined to ¥5.60B (-19.6%), Ordinary Income to ¥6.09B (-20.5%), and Net Income to ¥2.62B (-47.9%), with the decline widening further down the income statement. The approximately 15 bp decline in gross margin and SG&A expenses increasing faster than revenue (+5.1%) were the primary causes of the decline in Operating Income. In addition, extraordinary losses of ¥1.02B, including an impairment loss on investment securities of ¥0.75B, and the high effective tax burden of 48.6% significantly reduced Net Income.

Factors Affecting Financial Performance

【Revenue】Revenue increased to ¥788.96B, up +4.1% YoY. While the wholesale business for ethical pharmaceuticals and other products, the core business, which accounted for 89.9% of the revenue mix, led growth at +4.6%, the wholesale business for self-medication products declined by -1.1% and the manufacturing business for pharmaceuticals and other products contracted by -5.3%. The dispensing pharmacy and other businesses recorded modest revenue growth of +3.6%. Growth remains concentrated in the core wholesale business.

【Profit and Loss】Operating Income was ¥5.60B (-19.6% YoY), Ordinary Income was ¥6.09B (-20.5%), and Net Income was ¥2.62B (-47.9%), with the decline widening further down the income statement. The decline in gross margin to 6.7% from 6.8% in the previous year, together with SG&A expenses increasing by +5.1%, exceeding the revenue growth rate, was the primary cause of the decline in Operating Income. The ¥0.98B gap between Ordinary Income and Profit Before Tax of ¥5.10B resulted from extraordinary losses of ¥1.02B, including an impairment loss on investment securities of ¥0.75B, and can be viewed as a temporary factor. In addition, the high effective tax burden of 48.6% put pressure on Net Income. In addition to higher revenue and lower earnings, the combination of extraordinary losses and the high tax burden amplified the substantial decline in Net Income, which is a defining feature of this financial result.

Segment Analysis

The wholesale business for ethical pharmaceuticals and other products secured higher revenue of ¥70.98B (+4.6% YoY), but Operating Income was ¥0.662B (-0.2%), virtually flat, and its profit margin declined from the previous year to 0.9%. The fact that revenue growth has not translated into profit is the most important issue facing this key business. The wholesale business for self-medication products recorded lower revenue of ¥6.617B (-1.1%) and profit of ¥0.054B (-40.4%), resulting in lower revenue and earnings, while its profit margin also declined to 0.8%. Against revenue of ¥1.196B (-5.3%), the manufacturing business for pharmaceuticals and other products posted an Operating Loss of ¥0.62B, an expansion from the ¥0.06B loss in the same period of the previous year. The dispensing pharmacy and other businesses recorded higher revenue of ¥0.944B (+3.6%), but their Operating Loss expanded to ¥0.50B from a loss of ¥0.44B in the same period of the previous year. The structure is one in which declining profitability in the core wholesale business and the continued and expanding losses in the three non-wholesale businesses are suppressing consolidated earnings.

Key Financial Indicators

【Profitability】Both the Operating Margin of 0.7% (0.9% in the previous year) and Net Profit Margin of 0.3% (0.7% in the previous year) declined. Annualized ROE was 2.2%, while annualized ROIC was 3.6%, both at low levels. 【Cash Flow Quality】Accounts receivable stood at ¥69.871B, with annualized DSO at approximately 81 days, a relatively long period. Commercial transactions, including Accounts Payable of ¥91.417B, account for most of the assets and liabilities, reflecting the large working-capital structure characteristic of the wholesale industry. 【Investment Efficiency】Asset turnover is showing an improving trend, but given the low-margin, high-volume business structure, there are limits to improving capital efficiency through higher turnover alone. 【Financial Soundness】The Equity Ratio was 32.2% (33.7% in the previous year), while the D/E ratio was high at 2.10x. However, Accounts Payable represents the core of liabilities, and Interest Coverage was 56.5x against Interest Expense of ¥0.099B, indicating stable debt-servicing capacity.

Cash Flow Analysis

Although detailed disclosure of the cash flow statement is not available, changes in the balance sheet provide insight into fund flows. Cash and deposits decreased by ¥1.480B to ¥17.827B from ¥19.307B in the same period of the previous year, while treasury stock increased by ¥1.499B YoY to ¥3.654B, suggesting that funds may have been directed toward shareholder returns and capital allocation. Accounts receivable of ¥69.871B and inventories of ¥16.177B remained at approximately the same levels as in the previous year, indicating that the increase in working capital accompanying business expansion affected the cash balance. Cash and deposits of ¥17.827B substantially exceeded long-term borrowings of ¥1.00B and bonds of ¥2.00B, ensuring a sufficient liquidity safety buffer.

Earnings Quality

Non-operating income was ¥0.75B, representing only 0.1% of revenue, indicating limited reliance on non-operating income for Ordinary Income. The ¥0.98B gap between Ordinary Income of ¥6.09B and Profit Before Tax of ¥5.10B was primarily attributable to extraordinary losses of ¥1.02B, including an impairment loss on investment securities of ¥0.75B, and can be distinguished as a temporary factor outside the core business. The effective tax rate was high at 48.6%, amplifying the reduction from Profit Before Tax to Net Income. Accordingly, the -47.9% YoY decline in Net Income resulted from the layered effects of temporary and non-recurring factors—the impairment loss on investment securities and high tax burden—in addition to the deterioration in core-business profitability, reflected in the -19.6% decline in Operating Income. These factors should be evaluated separately from the underlying earning power of the core business.

Earnings Forecast and Guidance

Q1 progress toward the full-year company forecast was 25.1% for Revenue, 16.5% for Operating Income, 16.6% for Ordinary Income, and 11.9% for Net Income. Revenue was approximately in line with the standard 25% progress rate, while the earnings indicators were significantly below the standard level. The delay in Operating Income progress reflects the decline in gross margin, higher SG&A expenses, and the expansion of loss-making segments. The further delay in Net Income progress was attributable to extraordinary losses and the high tax burden. Neither the earnings forecast nor the dividend forecast has been revised, and the company maintains its plan based on an earnings recovery in the second half of the fiscal year.

Shareholder Returns

The full-year dividend forecast is ¥71.00 per share, and the full-year EPS forecast is ¥116.47, implying a forecast Payout Ratio of approximately 61.0%. The dividend forecast is higher than the previous-year dividend of ¥34 (interim), but no revision has been announced, and implementation as planned is expected. Since the Q1 Net Income progress rate was only 11.9%, achievement of the full-year earnings plan will directly affect dividend sustainability. Treasury stock also increased by ¥1.499B YoY, warranting attention to capital allocation in addition to dividends.

Risk Factors

1. Risk of margin compression in the core business: The wholesale business for ethical pharmaceuticals and other products recorded revenue growth of +4.6%, while segment profit was virtually flat at -0.2%. Thin margins could be compressed further by fluctuations in purchasing terms, price negotiations, and logistics costs.

2. Risk of expanding losses in non-wholesale businesses: Both the manufacturing business for pharmaceuticals and other products (Operating Loss of ¥0.62B, compared with ¥0.06B in the previous year) and the dispensing pharmacy and other businesses (Operating Loss of ¥0.50B, compared with a ¥0.44B loss in the previous year) reported wider losses. Delays in improvement could continue to weigh on consolidated profitability.

3. Risk associated with the high tax burden and working-capital structure: The effective tax rate of 48.6% may amplify fluctuations in Profit Before Tax in Net Income. In addition, annualized DSO for Accounts Receivable was approximately 81 days, requiring monitoring of capital efficiency together with the working-capital structure’s high dependence on Accounts Payable.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (trading)

Profitability and Returns

The Company’s Operating Margin and Net Profit Margin are both significantly below the industry median, placing its profitability at a low level within the industry.

Growth and Capital Efficiency

The Revenue Growth Rate is slightly above the industry median, but remains within the IQR, and any notable advantage is limited.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Although Revenue growth has been maintained at approximately the industry-average level, the Operating Margin and Net Profit Margin are significantly below the industry median, indicating from the financial results that revenue growth is not translating into earnings growth.

2. The core wholesale business for ethical pharmaceuticals and other products recorded higher revenue, but segment profit was virtually flat, suggesting that the profitability of the core business itself may be declining structurally. The expansion of losses in the manufacturing and dispensing pharmacy and other businesses is also observable as a structural issue.

3. The Net Income decline of -47.9% substantially exceeded the Operating Income decline of -19.6% because temporary and non-recurring factors—extraordinary losses including an impairment loss on investment securities and the effective tax rate of 48.6%—overlapped. This should be viewed separately from the decline in the profitability of the core business.

Theoretical Share Price (Reference Value)

Sensitivity: ¥2,340–¥2,473 at Cost of Equity ±1%, and ¥2,393–¥2,412 at ω±0.1.

Notes:

• Since forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit five-year fade) / Interest-rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action, nor does it predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---